The U.S. FDA issued a final rule intended to provide more flexibility in preclinical safety development by clarifying that nonanimal methods can be used where appropriate for assessing safety of drugs and biologics intended for human use. The agency framed the update as another step away from mandatory animal testing under certain testing needs. The rule aims to expand the range of acceptable approaches during preclinical development, potentially shortening workstreams where nonanimal platforms can substitute for traditional animal studies. For sponsors, this can influence early development planning, vendor strategy, and IND-enabling timelines. The FDA’s update also fits broader modernization efforts in CMC and preclinical strategy, reinforcing that regulatory acceptance increasingly depends on scientific justification for method suitability rather than on a default animal-testing requirement.